Probicol IBS

Probicol IBS is available in the form of oral capsules, each capsule containing a minimum of 20×10⁹ colony-forming units (CFU) of Lactobacillus plantarum 299v. This formulation allows for controlled release of the bacterial strain into the intestine, protecting the probiotic integrity in the acidic environment of the stomach and ensuring the effectiveness of intestinal colonization.

Probicol capsules are particularly recommended for people diagnosed with irritable bowel syndrome, in all its subtypes (with a predominance of constipation, diarrhea, or mixed forms). The supplement contributes to:

• balancing the intestinal bacterial ecosystem in dysbiosis associated with irritable bowel syndrome
• modulating the immune response in the gastrointestinal tract and subclinical inflammatory processes
• relieving digestive symptoms such as abdominal pain, bloating, flatulence, and postprandial discomfort.

In addition to its main indication, Probicol IBS may also be useful as an adjunct in various gastrointestinal disorders accompanied by microbiota imbalances or after antibiotic treatment.

The recommended dose is 1 capsule per day, taken orally, preferably with a meal or as recommended by your doctor.

It is important to allow at least 2 hours between taking antibiotics and Probicol IBS to avoid inactivation of the probiotic strain by the antimicrobial substances.

Probicol IBS is generally well tolerated, but is not recommended without medical advice in the following situations:

• people undergoing immunosuppressive treatment or with a weakened immune system
• patients with recurrent vaginal/urinary infections
• people with central venous catheters

patients who have recently undergone surgery

patients with rectal bleeding

people with known hypersensitivity to any of the product's components

In these cases, administration should only be carried out on the express recommendation of the attending physician, who will assess the potential risk of bacterial translocation and the patient's immune status.

Lactobacillus plantarum 299v is a probiotic strain with unique characteristics:

• has the ability to adhere to the intestinal mucosa
• ferments carbohydrates and contributes to the formation of a favorable environment for healthy microflora
• stimulates the production of intestinal mucus, acting as a physical barrier against pathogens
• inhibits the colonization of pathogenic bacteria by competing for adhesion sites

In addition, clinical studies suggest that this strain has a beneficial effect on the diversity of the intestinal microbiota, an important marker of digestive health.

In general, Probicol IBS is well tolerated by most patients. Adverse reactions are rare and mild, including:

• mild abdominal distension or flatulence in the first few days of administration,
• rarely, hypersensitivity reactions to excipients or capsule components.

These effects usually disappear spontaneously as the intestinal flora adapts and do not require discontinuation of administration.

Probicol IBS does not interact with most foods or drugs. However, it is recommended to wait 2 hours after taking antibiotics to prevent destruction of the probiotic strain.

Concomitant administration with prebiotics (soluble fiber) may enhance probiotic efficacy through synergy (synbiotic effect).

To date, no cases of overdose with Probicol IBS have been reported. Accidental administration of doses higher than those recommended is not generally associated with toxic effects, given the high safety profile of Lactobacillus plantarum 299v. However, in cases of severe gastrointestinal discomfort, it is recommended to consult a doctor.

To maintain the viability of the probiotic strain, Probicol IBS should be stored at room temperature, away from moisture and light, preferably below 25°C, in the original, tightly closed packaging. Keep out of reach of small children. The product does not require refrigeration, making it practical and easy to use.

• PubMed, Role of Lactobacillus plantarum 299v in supporting the treatment of selected diseases
• PubMed, Clinical study: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome
• Tandfonline, Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome
• MDPI, Psychobiotics as an intervention in the treatment of irritable bowel syndrome: A systematic review
• WebMD, Lactobacillus plantarum